Please login to the form below

Not currently logged in
Email:
Password:

Alain Thibault joins Argen-X as chief medical officer

Dutch biotech also appoints Jacobus Rasser as IP counsel

Netherlands-based preclinical biotech Argen-X has made two senior appointments, hiring former head of oncology at Regeneron Pharmaceuticals Dr Alain Thibault as chief medical officer and Dr Jacobus (Koos) Rasser as IP counsel.

Thibault will lead research efforts at the company, which is focused on developing antibodies as treatments in several therapeutic areas and has an alliance with Shire to investigate new treatments for rare diseases.

At Regeneron, Thibault gained experience in clinical development, product strategy and portfolio management, and led clinical development of eye disease treatment VEGF Trap (aflibercept), which was developed in partnership with Sanofi.

He also led research into the fully human antibody products REGN 421 and REGN 910.

Prior to joining Regeneron, Thibault held senior research positions at Johnson & Johnson and Hoffman-La Roche before joining Regeneron.

Rasser joins Argen-X from global IP law firm Howrey LLP. While at Howrey, his pharma clients included Biogen Idec, Millennium Pharmaceuticals, Eppendorf, Schering Plough and Amersham.

His previous roles include serving as head of the global IP organisation at Procter & Gamble, where he was responsible for a portfolio of more than 2,000 patent families.

Tim Van Hauwermeiren, CEO at Argen-X, said: "As the quality and productivity of our Simple Antibody platform translates consistently into clinical development opportunities and valuable new intellectual property, their expertise will be fundamental to attaining our ambitious business goals and reaching our next value inflection point as a company."

20th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics